Considering the empirical evidence that individuals diagnosed with non-small celllung cancer (NSCLC) demonstrate a heightened prevalence of Covid-19, coupled with the manifestation of more severe symptoms andunfavourable prognoses, it is plausible to assert that the elevated expression of MALAT1 in NSCLC patients may impede the innateantiviral defence mechanisms, thereby augmenting their vulnerability to SARS-CoV-2 infection. This evidence concerns the gene MALAT1 and non-small cell lung carcinoma.